Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE Voglibose and acarbose are distinguished α-glucosidase inhibitors used for controlling of diabetes mellitus. 31699396 2020
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE This review provides a comprehensive understanding on the use of flavonoids as αA and αG inhibitors for controlling diabetes. 30638035 2020
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 GeneticVariation group BEFREE After adjusting for age, gender, ethnicity, body mass index, smoking status, socioeconomic status, hypertension, hyperlipidaemia, diabetes, duration of diabetes and cardiovascular disease, ACE inhibitors (OR=1.27; 95% CI 1.05 to 1.55), fibrates (OR=1.57; 95% CI 1.05 to 2.35), alpha-glucosidase inhibitors (AGIs) (OR=1.85; 95% CI 1.13 to 3.02) and insulin (OR=1.80; 95% CI 1.11 to 2.93) were significantly associated with the presence of cortical cataract. 31272959 2020
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 GeneticVariation group BEFREE Chalcones, originated from natural product, have been broadly studied their biological activity against various proteins which at the molecular level, are responsible for the progress of the diseases in cancer (e.g. kinases), inflammation (oxidoreductases), atherosclerosis (cathepsins receptor), and diabetes (e.g.α-glucosidase). 31808389 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE The findings of this work supported that N. oleracea is a rich source of phenolics that can be potential antioxidants and α-glucosidase inhibitors for the management of diabetes. 30616569 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE Peptide-based therapeutics offer a unique avenue for the development of novel agents for the treatment of diabetes mellitus including α-glucosidase inhibitors. 30919765 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 AlteredExpression group BEFREE Increased α-glucosidase, PEPCK, GLUT-2 and SGLTs levels with the induction of diabetes considerably lowered with TPSE treatment. 30399410 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE Since hypoglycemia can occur in diabetes disease and there is a significant link between diabetes and cardiovascular diseases (CVD), thus this study aimed to evaluate the inhibitory properties of DP against α-Amy and α-Glu, as enzyme targets of interest under hypoglycemia condition. 31078769 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE Anti-α-glucosidase (AAG) compounds have received great attention due to their potential use in treating diabetes. 30769933 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE α-Glucosidase inhibitors have been approved as therapeutic agents for diabetes. 31555798 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 GeneticVariation group BEFREE EAE was the most effective enzyme inhibitor, exhibiting the highest inhibition against some enzymes linked to Alzheimer's disease (cholinesterases), diabetes mellitus (α-glucosidase and α-amylase) and hyperpigmentation problems (tyrosinase). 30466026 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE α-Glucosidase and its inhibitors play a key role in diagnosis and treatment of diabetes. 31670357 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE Given the possibility of developing in diabetics and the significant association between diabetes and infection, the present study was conducted to investigate the influences of tetracycline (TET), kanamycin (KANA), lincomycin (LIN), erythromycin (ERM) and azithromycin (AZM) on α-glucosidase and α-amylase activities with calculating IC<sub>50</sub> and K<sub>i</sub> values. 31400388 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE Postprandial hyperglycemia can be reduced by inhibiting major carbohydrate hydrolyzing enzymes, such as α-glucosidase and α-amylase which is an effective approach in both preventing and treating diabetes. 30251608 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE As the most common drugs for diabetes mellitus, synthetic compounds can also be classified into several categories according to their working mechanisms, such as insulin secretion promotor agents, insulin sensitizer agents, α-glucosidase inhibitors, and so forth. 31214029 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE The carbohydrates require metabolism by α-glucosidase before being absorbed into the small intestine, and as a result, this enzyme represents a significant drug target for the effective management of diabetes. 30484413 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE Human α-glucosidase is an enzyme involved in the catalytic cleavage of the glucoside bond and involved in numerous functionalities of the organism, as well as in the insurgence of diabetes mellitus 2 and obesity. 29421954 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE The water extracts had the highest antioxidant activity, especially those from roots and flowers, and were further appraised for in vitro inhibition of enzymes implicated on the onset of human ailments, namely acetyl- (AChE) and butyrylcholinesterase (BuChE) for Alzheimer's disease, α-glucosidase and α-amylase for diabetes, and tyrosinase for skin hyperpigmentation disorders. 30529825 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE α-Glucosidase is a critical enzyme associated with diabetes mellitus, and the inhibitors of the enzyme play important roles in the treatment of the disease. 30227201 2019
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE The inhibitory action of F. halophila extracts (acetone, chloroform, and methanol) against key enzymes linked to diabetes (α-amylase, α-glucosidase), cognitive functions (acetyl cholinesterase (AChE), butyryl cholinesterase (BChE)), and hyperpigmentation (tyrosinase) was assessed. 30121555 2018
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE The results demonstrate that ultrafiltration with liquid chromatography and mass spectrometry combined with high-speed counter-current chromatography is not only a powerful tool for screening and isolating α-glucosidase and lactate dehydrogenase inhibitors in complex samples, but also a useful platform for identifying bioactive compounds for preventing and treating diabetes and stroke. 30444083 2018
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 GeneticVariation group BEFREE Accordingly, nutritional composition, the content of phytochemical antioxidants, and the inhibitory ability of key enzymes with impacts on obesity and diabetes (α-glucosidase and pancreatic lipase) or on arterial pressure (angiotensin-I converting enzyme), were evaluated. 30274353 2018
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE Taken altogether, in vitro and in vivo experiments suggest that selected natural compounds (curcumin, antroquinonol, HCD, docosanol, tetracosanol, rutin, and actinodaphnine) via molecular docking were confirmed as potential candidates of α-glucosidase and α-amylase inhibitors for treating diabetes. 30189596 2018
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 Biomarker group BEFREE Gray, and <i>Salvia officinalis</i> L. decoctions were investigated for their health-benefit properties, in particular with respect to antioxidant activity and inhibitory ability towards key enzymes with impact in diabetes and obesity (α-glucosidase, α-amylase and pancreatic lipase). 30513773 2018
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 AlteredExpression group BEFREE The inhibition of α-glucosidase, a key carbohydrate hydrolyzing enzyme, could serve as one of the effective methodology in both preventing and treating diabetes through controlling the postprandial glucose levels and suppressing postprandial hyperglycemia. 29421697 2018